Novel simplified bioinformatics for NGS data analysis | Marc Noguera-Julian, PhD

European Meeting on HIV & Hepatitis 2018

New technologies reaching the clinic | Martin Däumer, MSc

European Meeting on HIV & Hepatitis 2018

Implications for clinical practice | Jonathan Schapiro, MD

European Meeting on HIV & Hepatitis 2018

Clinical trial data 3 vs 2 drug regimens | Andrea De Luca, MD

European Meeting on HIV & Hepatitis 2018

Influence of resistance in the future | Richard Harrigan, MD

European Meeting on HIV & Hepatitis 2018

The current status of PrEP in Europe | Pep Coll, MD

European Meeting on HIV & Hepatitis 2018

A new wild-type HIV in the era of transmitted drug resistance | Kristof Theys, PhD

European Meeting on HIV & Hepatitis 2018

Long acting HIV drugs for prevention: what are the data? | Pep Coll, MD

European Meeting on HIV & Hepatitis 2018

Long acting HIV drugs for treatment: what are the data? | Anton Pozniak, MD, FRCP

European Meeting on HIV & Hepatitis 2018

Improving drug delivery: what are the new technologies? | Saye Khoo, MD, PhD

European Meeting on HIV & Hepatitis 2018

How would the epidemic evolve in the future | David van de Vijver, PHARMD, PHD

European Meeting on HIV & Hepatitis 2018

The HIV epidemic in CEE countries | Oana Săndulescu, MD, PhD

European Meeting on HIV & Hepatitis 2018

HIV PrEP | Pep Coll, MD

Central and Eastern European Meeting on Viral Hepatitis and HIV 2018

New delivery systems and long acting antiretroviral drugs | David Back, PhD

Central and Eastern European Meeting on Viral Hepatitis and HIV 2018

The EpiTer-2 database | Robert Flisiak, MD, PhD

Central and Eastern European Meeting on Viral Hepatitis and HIV 2018

Liver transplantation for HCV and HBV in The Czech Republic | Soña Frankova, MD, PhD

Central and Eastern European Meeting on Viral Hepatitis and HIV 2018

Clinical considerations in switching antiretroviral therapy | David Jilich, MD

Central and Eastern European Meeting on Viral Hepatitis and HIV 2018

Treatment-experienced patients in Central and Eastern Europe – What needs to be done? | Viktor Aster, MD, PhD

Central and Eastern European Meeting on Viral Hepatitis and HIV 2018

HIV & women’s health: do we have any game changers here? | Mariana Mărdărescu, MD, PhD

Central and Eastern European Meeting on Viral Hepatitis and HIV 2018

Hepatitis Delta: what are the new developments, what are the challenges? | Cihan Yurdaydin, MD

Central and Eastern European Meeting on Viral Hepatitis and HIV 2018

Update on changes in Hepatitis B and C in CEE countries | Miłosz Parczewski, MD, PhD

Central and Eastern European Meeting on Viral Hepatitis and HIV 2018

Epidemiology of HIV Infection and Treatment in Europe | Teymur Noori, MSc

Central and Eastern European Meeting on Viral Hepatitis and HIV 2018

European Meeting on HIV & Hepatitis 2021

Challenges to Widespread PrEP in Europe: Social Aspects - Michael Meulbroek

European Meeting on HIV & Hepatitis 2020